Johns Hopkins Medicine researchers have supported the first FDA-cleared rapid urine test for invasive aspergillosis after clinical validation. The work is designed to improve early diagnostic identification, using urine-based sampling to help distinguish invasive disease from non-invasive presentations. Rapid tests can shift patient management by shortening time to diagnosis and enabling earlier initiation of appropriate antifungal therapy—particularly in high-risk groups where delays can be consequential. The clearance also signals regulator confidence in clinical performance evidence derived from validation cohorts. The development matters for biotech diagnostics portfolios because urine-based assays can streamline testing workflows compared with more invasive sampling, potentially widening adoption in busy clinical pathways.